Venionaire Capital
Venionaire DealMatrix launches “Venionaire DealMatrix Multiples” – time series-based PE and VC valuation multiples filtered by sector, company phase, and region
Venionaire DealMatrix, a subsidiary of Venionaire Capital, announces the launch of Venionaire DealMatrix Multiples. The new product provides private equity and venture capital multiples (EV/Sales and EV/EBITDA) covering over 140 sectors, allowing granular filtering by company stage from pre-seed to Series E and global regions, and tracking their development over time. This creates a robust reference framework for valuing private companies.
Mehr
LTAT #62
The Defense Tech Gold Rush – Andreas Perotti | Let’s Talk About Tech #62
In this episode of Let’s Talk About Tech, I sit down with Andreas Perotti, Defense Tech expert and entrepreneur to explore how defense exploded after 2022 and whether true technological resilience is even possible in a globalized world.
MEET THE TEAM
An overview about our expert team with the possibility for direct contact. Feel free to let them know that you are there!
SCHEDULE AN APPOINTMENT
WHERE TO FIND US
VIENNA, OFFICE (HQ)
Babenbergerstraße 9/12,
A-1010 Vienna, Austria (EU)
office@venionaire.com
SAN FRANCISCO, USA
1355 Market St. #488
San Francisco CA 94103
sfo@venionaire.com
NEW YORK CITY, USA
122 East 37th Street
First Floor
New York, NY 10016
nyc@venionaire.com
LONDON, UK
Gable House, 239 Regents Park Road
London N3 3LF
office@venionaire.com
Luxembourg, LUX
28, Boulevard F.W. Raiffeisen
2411 Luxembourg
office@venionaire.com
SITEMAP
LOOKING FOR FUNDING?
FOR STARTUPS
Venionaire Capital exclusively invests through the European Super Angels Club, for more information and application please go to the website. We do not accept direct investment proposals via this website.
Longevity Tech: How Personalized Medicine, Neurofeedback, and Mitochondrial Health Are Redefining Lifespan
/in Insights, News, Tech /by VenionaireLongevity is no longer a niche topic reserved for academic research—it is rapidly becoming one of the most dynamic frontiers in healthcare innovation and venture capital. As discussed in a recent episode of Let’s Talk About Tech, the convergence of personalized medicine, advanced diagnostics, and emerging therapies is reshaping how we think about aging, healthspan, and performance.